The Vasculitis Treatment Market size was estimated at USD 1.66 billion in 2025 and expected to reach USD 1.75 billion in 2026, at a CAGR of 5.31% to reach USD 2.39 billion by 2032.

Vasculitis treatment is moving from emergency inflammation control toward precision, organ-protective, steroid-sparing care for rare autoimmune blood vessel disorders. The therapeutic landscape spans ANCA-associated vasculitis treatment for granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis; giant cell arteritis treatment; Takayasu arteritis management; immune-complex vasculitis; and pediatric vasculitis pathways. Clinical priorities are consistent across these diseases: accelerate diagnosis, induce remission, prevent relapse, preserve kidney, lung, vascular, neurologic, and ocular function, and reduce glucocorticoid toxicity. Data confirm the rarity and complexity of the field: a worldwide meta-analysis estimated ANCA-associated vasculitis incidence at 17.2 per million person-years and prevalence at 198 per million persons, while a giant cell arteritis meta-analysis found a pooled incidence of 10.00 cases per 100,000 people over age 50, with higher rates in Scandinavia and North America. The executive imperative is therefore not volume-driven positioning, but evidence-led differentiation through validated biomarkers, imaging-enabled diagnosis, renal and pulmonary risk stratification, real-world safety surveillance, and equitable access to multidisciplinary vasculitis care.

The vasculitis treatment landscape is undergoing a structural shift from prolonged high-dose glucocorticoid dependence toward risk-adapted immunosuppressive therapy, biologic therapy, and tighter safety governance. Current ANCA-associated vasculitis guidance supports remission induction with glucocorticoids plus rituximab or cyclophosphamide for organ-threatening disease, while kidney-focused guidance emphasizes that therapy choice should account for relapse history, PR3-ANCA or MPO-ANCA subtype, fertility, frailty, severe glomerulonephritis, and infection risk. Evidence from major trials and guideline updates has also normalized faster glucocorticoid tapering, especially after findings that reduced-dose regimens can maintain efficacy while lowering infectious toxicity in severe ANCA-associated vasculitis. Large-vessel vasculitis is shifting as well: 2023 imaging recommendations place ultrasound as the first-line imaging test for suspected giant cell arteritis and MRI as the preferred imaging modality for Takayasu arteritis, moving care pathways closer to rapid, noninvasive diagnosis. The most disruptive 2026 development is regulatory reassessment of avacopan: European regulators began a review on January 30, 2026, over data-integrity concerns, and the U.S. regulator proposed withdrawal on April 27, 2026, while noting the therapy remained available pending a final decision.

Artificial intelligence is becoming a cumulative enabler across vasculitis diagnosis, clinical trial enrichment, treatment monitoring, and post-authorization safety surveillance, but its evidence base remains early and must be externally validated. In giant cell arteritis, a systematic review of artificial intelligence and predictive analytics searched literature through September 2024, identified 309 studies, and included only four that met criteria, indicating promising but still immature evidence for AI-supported ultrasound interpretation, diagnostic prediction, and relapse-risk modeling. In ANCA-associated vasculitis, deep learning and natural language processing are improving cohort discovery from electronic health records, an important capability because rare disease research is limited by fragmented case identification and inconsistent capture of organ involvement, relapse, infection, and glucocorticoid exposure. In renal vasculitis, digital pathology is also emerging: a deep learning classification study for ANCA-associated glomerulonephritis used kidney biopsy slides from 80 patients across three European centers, demonstrating how AI could support reproducible lesion classification and damage assessment when linked with expert nephropathology review. The practical impact for vasculitis treatment is cumulative rather than instantaneous: AI can shorten diagnostic delays, flag multisystem symptom clusters, support imaging triage, identify trial-ready patients, and strengthen pharmacovigilance, provided governance covers bias, explainability, privacy, audit trails, and clinician accountability.

Europe remains a guideline- and health-technology-assessment-led environment for vasculitis treatment, supported by EULAR recommendations, advanced ultrasound adoption for giant cell arteritis, and centralized regulatory review for high-impact therapies such as avacopan. North America is characterized by strong specialty society guidance, high clinical trial participation, and active safety oversight, with U.S. guidance covering ANCA-associated vasculitis, giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, and Kawasaki disease, and 2026 U.S. regulatory actions reinforcing the need for post-authorization evidence discipline. Asia-Pacific has distinct epidemiologic and clinical priorities: Japan and China show higher relative representation of MPO-ANCA and microscopic polyangiitis patterns than many Western cohorts, Takayasu arteritis has comparatively higher reporting in Asian populations, and Australia has incorporated avacopan into regulated AAV treatment options while still needing careful alignment with evolving safety signals. Latin America is shaped by heterogeneous access and increasing regional guideline development, with tailored ANCA-associated vasculitis recommendations acknowledging disparities in access to higher-cost therapies and expertise. The Middle East is strategically important for Behçet disease and complex multisystem vasculitis because Behçet clusters along the historic Silk Road, including Mediterranean and Middle Eastern populations. Africa requires capacity-building in diagnostics, registries, and specialist referral because vasculitis data remain scarce, with systematic reviews finding no African AAV epidemiology studies and regional reviews emphasizing limited published evidence.

Across NATO countries as an analytical cohort, vasculitis treatment priorities center on resilient specialty referral, reliable immunology laboratories, rapid renal and pulmonary escalation pathways, and harmonized pharmacovigilance, although NATO itself does not standardize healthcare delivery. G7 countries are especially relevant for giant cell arteritis treatment because the disease is concentrated in adults over 50 and is well documented in Europe and North America, while their established regulatory and payer systems make them early adopters of guideline-driven steroid-sparing strategies. The European Union provides a distinctive framework through EULAR guideline diffusion, centralized medicine review, cross-country safety communication, and standardized reassessment mechanisms, illustrated by the 2026 European review of avacopan. BRICS countries require a dual lens: China, India, Brazil, Russia, and South Africa include populations where Takayasu arteritis, AAV phenotype variation, infectious mimics, and referral inequities can materially change treatment decisions, making registries, biospecimen networks, and standardized ANCA testing essential. ASEAN systems face similar needs for specialist hubs, imaging capacity, and affordable maintenance therapy, especially because Takayasu arteritis has historically been reported more often in Southeast Asia, India, Japan, and Mexico than in many Western settings. GCC countries should prioritize Behçet disease expertise, biologic safety monitoring, and cross-border referral protocols because Middle Eastern populations sit within high-prevalence Behçet geographies.

The United States is defined by comprehensive vasculitis guidelines and heightened 2026 regulatory scrutiny of avacopan, making real-world evidence, hepatic monitoring, and transparent benefit-risk communication central to ANCA-associated vasculitis treatment. Canada aligns with North American referral and guideline pathways, with emphasis on rare disease coordination, renal vasculitis care, and timely access to specialty immunology testing. China and Japan require particular attention to MPO-ANCA and microscopic polyangiitis patterns, and Japan is also prominent in the 2026 hepatic safety signal review because most reported drug-induced liver injury cases assessed by the U.S. regulator came from Japan. Germany, France, Italy, and Spain sit within the EULAR and European regulatory ecosystem, where ultrasound-first giant cell arteritis diagnosis, AAV glucocorticoid reduction, and post-authorization evidence review are key adoption drivers. The United Kingdom combines European-style fast-track vasculitis diagnostics with national evidence appraisal; published guidance has recommended avacopan within its authorization for severe active granulomatosis with polyangiitis or microscopic polyangiitis, but current leaders should monitor evolving 2026 safety and data-integrity reviews. India and Mexico are important for Takayasu arteritis recognition, while Brazil has a growing tertiary-care evidence base and participates in Latin America-focused AAV guideline development. Russia should be treated as a BRICS-aligned priority for standardized referral, renal biopsy capacity, and safety registries across large geographies. Australia has regulated access to avacopan for AAV in combination regimens, while South Korea provides a model for population-level AAV monitoring through national insurance data analyses.

Industry leaders should prioritize evidence generation over promotional expansion by building registry-linked vasculitis programs that capture organ involvement, ANCA subtype, kidney function, relapse, infection, glucocorticoid exposure, liver safety, pregnancy considerations, and patient-reported outcomes. Treatment developers and clinical leaders should design steroid-sparing strategies around validated endpoints such as remission, sustained remission, relapse-free survival, renal survival, cumulative glucocorticoid dose, serious infection, and irreversible damage, not around broad inflammatory markers alone. The 2026 avacopan reassessment makes post-authorization surveillance a strategic necessity: leaders should strengthen hepatic monitoring protocols, transparent risk communication, and rapid evidence review processes before expanding any complement-targeted pathway. Health systems should establish fast-track giant cell arteritis ultrasound clinics, renal-lung vasculitis escalation pathways, multidisciplinary boards, and standardized infection screening before immunosuppression. AI investment should be focused on externally validated use cases, including EHR-based case finding, imaging triage, biopsy quantification, trial matching, and pharmacovigilance signal detection, with clinician oversight embedded from design to deployment.

This executive summary was developed through an evidence-led methodology that triangulated peer-reviewed randomized trials, systematic reviews, meta-analyses, clinical practice guidelines, regulatory communications, and regional epidemiology studies. Priority evidence sources included ANCA-associated vasculitis treatment guidelines, kidney-focused AAV guidance, large-vessel vasculitis imaging recommendations, AAV and GCA epidemiology meta-analyses, artificial intelligence studies in GCA, EHR-based AAV cohort identification, AI-enabled renal pathology research, and 2026 regulatory safety updates. Regional, group, and country insights were synthesized by connecting epidemiologic phenotype variation, guideline infrastructure, diagnostic capacity, health-system access, and safety governance. The methodology deliberately excluded market estimation, market sizing, market share, and forecasting, and instead focused on verifiable clinical, regulatory, epidemiologic, and operational evidence relevant to vasculitis treatment strategy. All interpretations were framed conservatively, with current safety and authorization uncertainty explicitly incorporated where the evidence base changed in 2026.

Vasculitis treatment is entering an evidence-intense phase in which rare disease expertise, precision immunosuppression, steroid-sparing protocols, imaging-first diagnosis, AI-supported case identification, and rigorous pharmacovigilance must operate together. The most successful strategies will address the full care pathway: early recognition of multisystem disease, accurate ANCA and biopsy interpretation, rapid treatment of organ-threatening inflammation, maintenance therapy tailored to relapse and infection risk, and long-term monitoring for kidney failure, vascular damage, cardiovascular complications, malignancy, hypogammaglobulinemia, and treatment toxicity. The 2026 reassessment of avacopan underscores that innovation in vasculitis treatment must be matched by durable evidence integrity and real-world safety monitoring. Regionally, Europe and North America lead guideline and regulatory standardization, Asia-Pacific contributes critical phenotype and pharmacovigilance insights, Latin America is advancing context-specific guidance, the Middle East requires Behçet-centered expertise, and Africa needs stronger epidemiology and diagnostic infrastructure. The strategic direction is clear: better outcomes in vasculitis treatment will depend on validated data, equitable access, multidisciplinary execution, and accountable adoption of targeted therapies and AI-enabled tools.